Sa. Narod et al., Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study, LANCET, 357(9267), 2001, pp. 1467-1470
Citations number
21
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background In several case-control and prospective studies, tubal ligation
has been associated with a decreased risk of invasive epithelial ovarian ca
ncer. We aimed to assess the potential of tubal ligation in reducing the ri
sk of ovarian cancer in women who carry predisposing mutations in the BRCA1
or BRCA2 genes.
Methods We did a matched case-control study among women from Canada, the US
A, and the UK who had undergone genetic testing and who carried a pathogeni
c mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasi
ve ovarian cancer, and controls were 232 women without ovarian cancer, and
who had both ovaries intact. Cases and controls were matched for year of bi
rth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio fo
r developing ovarian cancer was estimated for tubal ligation, adjusting for
oral contraceptive use, parity, history of breast cancer, and ethnic group
.
Findings In an unadjusted analysis among BRCA1 carriers, significantly fewe
r cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of
173 [35%], odds ratio 0.37 [95% CI 0.21-0.63]; p=0.0003). After adjustment
for oral contraceptive use, parity, history of breast cancer and ethnic gr
oup, the odds ratio was 0.39 (p=0.002). Combination of tubal ligation and p
ast use of an oral contraceptive was associated with an odds ratio of 0.28
(0.15-0.52). No protective effect of tubal ligation was seen among carriers
of the BRCA2 mutation.
Interpretation Tubal ligation is a feasible option to reduce the risk of ov
arian cancer in women with BRCA1 mutations who have completed childbearing.